Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The vaccine maker’s board intends to recommend a pending offer from investment firms Nordic Capital and Permira, which would ...

A deal with US WorldMeds includes the FDA-approved TCR therapy Tecelra and two clinical-stage cancer medicines.

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

The company can again ship the Duchenne gene therapy for patients who can still walk, following a one-week pause triggered by ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s ...

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...